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Rationale for Bariatric Surgery in Patients
with Cirrhosis
The obesity epidemic has grown dramatically, becoming a
public health concern.1 Since sustained weight loss with
lifestyle modifications alone remains difficult for many
individuals with severe obesity, bariatric surgery (BS) pro-
cedures (also recently termed “metabolic surgery”) have
become increasingly common.2 The liver-related benefits
resulting from BS are mostly related to the marked weight
loss following these procedures. Additionally, glucagon-like
peptide-1 (GLP-1) levels, which increase satiation, improve
insulin sensitivity, and alter the modulation of bile acid
signaling, increase after BS, and this has been linked to a
positive shift in the gut-liver axis mediated by Farnesoid X
receptor.3,4 Long-term benefits of BS include long-term
weight loss, remission of metabolic risk factors such as
diabetes, dyslipidemia, and hypertension,5 and improved
long-term mortality.6 In patients with cirrhosis and obesity,
weight loss targeting 10% of body weight is a major thera-
peutic goal, as it associates with NASH histologic improve-
ment and, since obesity per se associates with higher risk of
decompensation, hepatocellular carcinoma, portal vein
thrombosis, and acute on chronic liver failure.7
Patients with obesity whomeet the criteria for BS, namely







► alcohol use disorders
Abstract Theburdenof obesity andmetabolic syndromehas determined a sharp increase in bariatric
surgery (BS) procedures,which lead tomarkedweight loss, improvedmetabolic syndrome,
reduced cardiovascular risk, and even improvement in nonalcoholic steatohepatitis
(NASH). Despite these promising results, BS in patients with chronic liver disease can
rarely lead toworseningof liver function, progression to cirrhosis and its complications, and
even liver transplantation. On the other hand, since obesity in patients with cirrhosis is a
major cofactor for progression to a decompensated stageof thediseaseanda risk factor for
hepatocellular carcinoma, BShas been used to achieveweight loss in this population. In this
review, we critically analyze the existing data on outcomes of BS in patients with cirrhosis
and thepossiblemechanisms leading tofibrosisprogressionandworsening liver function in
patients undergoing BS. Finally, we propose a set of measures that could be taken to
improve the multidisciplinary management of liver disease in patients undergoing BS,
including early recognition of malnutrition and alcohol misuse.
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and at least one or more obesity-related co-morbidities
frequently have features of nonalcoholic fatty liver disease
(NAFLD) or nonalcoholic steatohepatitis (NASH)/metabolic
liver disease (MAFLD).8,9 Indeed, BS has been proved to
improve long-term survival and death from cardiovascular
disease (CVD) andmalignancy, the twomost frequent causes
of death in patients with NASH.10 Several prospective and
retrospective cohort studies in NASH patients have shown
that sustained weight loss associates with reductions in
steatosis, inflammation, and fibrosis, already evident
1 year after BS.11–14 A recent meta-analysis from observa-
tional studies, which did not include patients with cirrhosis,
showed that 66% of patients achieved steatosis improve-
ment, 50 and 76% of patients improve the ballooning and
inflammation, respectively, and 40% of patients experienced
improved fibrosis. Interestingly, however, 12% of patients
showed de novo NAFLD and worsening of fibrosis.15
Progression of Liver Fibrosis after BS and
Feasibility and Safety of BS in Patients with
Cirrhosis
Despite the promising results of BS in NAFLD and its in-
creased use, there has been increased awareness of BS
complications. A systematic review showed that worsening
liver disease belongs to the spectrumof complications of BS16
and recent case series have reported the onset of cirrhosis
complicated by liver failure leading to liver transplantation
(LT).17–20 To date, one study specifically looked at the efficacy
and safety of BS in patients with compensated cirrhosis with
the majority of their patients having NASH/MAFLD.21 This
sleeve gastrectomy study showed excellent weight loss, and
metabolic improvement with no significant complications
despite some patients having mild portal hypertension on
endoscopy. The American Gastroenterological Association
(AGA) recently published a clinical practice guideline for BS
in cirrhosis, suggesting that BS can be considered in selected
patients with compensated cirrhosis but should only be
performed after careful evaluation and management of
extrahepatic comorbidities, and after assessing portal
hypertension.22
Indeed, in-hospital mortality rate after BS is higher in
patients with compensated cirrhosis versus patients without
cirrhosis (0.9 vs. 0.3%), and markedly increased in patients
with decompensated cirrhosis (16.3%).23 In a recent U.S.
nationwide population-based cohort, among 1,679,828
patients undergoing BS, 9,802 patients had cirrhosis.24 Mor-
tality was 1.81% in patients with cirrhosis and 0.17% in those
without cirrhosis. However, the authors reported a change in
the type of BS over the study period, shifting from mixed
procedures (RYGB and biliopancreatic diversion-BDP) to
restrictive procedures (SG, vertical banded gastroplasty,
and adjustable gastric banding-AGB) resulting in a lower
in-hospital complications and decreased mortality.24
The type of surgery is one of the criteria that should be
considered in balancing the risks and benefits of BS in
cirrhosis. A systematic reviewof the outcome of 122 patients
with compensated cirrhosis (96.5% Child-Pugh A, and 3.4%
Child-Pugh B) undergoing BS showed that mortality related
to BS was only observed in BPD and RYGB group at 20 and
3.9 %, respectively.25 Nomortality was observed with SG and
AGB. Overall, nine patients (7.3%) decompensated after
surgery, but all the decompensating episodes in SG patients
were self-limited, and none resulted in mortality.25 Long-
term data on the outcome of these patients is not available,
and specifically, it is not known to what extent cirrhosis can
regress in this situation. Long-term follow-up of a small
cohort of compensated cirrhotic patients with sleeve gas-
trectomy over 8 to 10 years did show sustained weight loss,
stable liver functionwith only one patient developing hepat-
ic encephalopathy (with coexisting mania complicating the
diagnosis) 3 years after BS. No progression of disease or liver
dysfunction was noted over the 10-year follow-up.26
Based on the published case series and on data regarding
elective extrahepatic surgery,27 severe portal hypertension
should be seen as a contraindication to BS. Two small series
showed that BS might be safe in cirrhosis patients and mild
portal hypertension, but one study reported a retrospective
experience, and both were limited to a single tertiary cen-
ter.21,28 Further large-scale studies arewarranted to evaluate
the safety and outcomes of BS in patients with cirrhosis and
portal hypertension, and the current AGA clinical practice
guidelines recommend avoiding BS in this situation.22
Based on the existing data, patients with compensated
cirrhosis (Child-Pugh class A) without severe portal hyper-
tension might be eligible for BS, and SG might be more
suitable in this setting. The decision should be taken on a
case-by-case basis, after having carefully assessed portal
hypertension.10,22 BS candidate patients with known cirrho-
sis or signs of bridging fibrosis would benefit frommeasure-
ment of the hepatic venous pressure gradient (HVPG), which
is the gold-standard method to evaluate portal hypertension
in patientswith chronic liver disease.29 If this is not available,
upper gastrointestinal endoscopy to identify/rule-out vari-
ces should be utilized.
Historically BS procedures with a marked malabsorptive
component, such as jejunoileal bypass (JIB) or BPD (Scopi-
naro procedure)were proven to cause severe life-threatening
complications including acute liver failure in up to 10% of
patient, and were therefore subsequently abandoned.30,31 In
a nationwide Belgian survey in 2010, 10 patients (nine of
them with BPD and one JIB) were listed for LT due to severe
liver failure after BS, with a median time of 5 years after the
weight-loss surgical procedure. The authors concluded that,
although rare, the BPD operation carries a potential risk of
life-threatening liver failure.32
More recently, Addeo and coworkers published a review
that included 14 studies, reporting an overall 36 patients
listed for LT after BS (mainly JIB and BPD). Liver failure
developed after a median of 20 months post-BS and was
significantly shorter after BPD. Four patients died while on
the waiting list for LT, and four additional patients died after
LT; 21 patients had their BS procedure reversed, mostly
simultaneously with LT. Explant histology documented ad-
vanced fibrosis/cirrhosis, as well as necrosis and massive
steatosis. Additionally, biopsy-proven steatosis recurrence
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after LT was reported in six patients, of whom four did not
undergo BS reversal.19
Because of this potentially fatal complication, malabsorp-
tive procedures have been progressively abandoned in favor
of restrictive procedures, more often achievable through
laparoscopic or mini-invasive approach (i.e., laparoscopic
adjustable gastric banding and SG),33 or procedures combin-
ing malabsorption and restriction (i.e., RYGB). New evidence
shows that liver damage progression can occur even after
these restrictive or partially restrictive procedures.20,34 In
this respect, a secondary analysis of a trial comparing the
effects of SG versus RYGB on liver function in bariatric
patients with NAFLD has shown that at 1 month after BS,
albumin value and INR were significantly more frequently
impaired in the RYGB group than in the SG group. Conversely,
at 12 months, the improvement in transaminases and gam-
ma-glutamyl transpeptidase (GGT) was more evident for SG.
The authors concluded that NAFLD patients undergoing
RYGB may be more prone to develop early transient deterio-
ration of liver function than after SG.35
In two recent studies, liver decompensation after BS was
described as an increasingly observed event, associated with
two key factors: malnutrition and alcohol use disorders.20,34
In the Swiss series, 3 out of 17 post-BS decompensated
patients underwent LT,whereas twowere still on thewaiting
list at the end of follow-up.20 In the Belgian study, the authors
compared patients listed for LT for alcoholic liver disease
with or without previous BS. They found that BS patients
were younger, with more severe decompensation and a
significantly shorter timeframe between diagnosis, listing,
and LT. Additionally, they showed comparable survival and
post-LT complication rates between patients with and with-
out BS.34
Bariatric Surgery and Liver Transplantation
Considering that NASH/MAFLD is becoming themost emerg-
ing indication for LT among adults, according to the European
Liver Transplant Registry (ELTR) and the United Network for
Organ Sharing (UNOS) databases,36,37 it can be expected that
an increasing prevalence of future LT candidates may have
had BS prior to LT. BMI  40kg/m2 is still considered a
surgical contraindication to LT inmany transplant programs,
thus, BS may allow access to the LT waiting list to morbidly
obese patients with end-stage liver disease at more trans-
plant centers.
Several studies addressed the clinical impact of prior BS
on post-LT outcomes. Serrano et al reported a similar length
of hospital stay and ICU stay after LT (5.3 vs. 4.1 days,
p¼0.16), a similar 30-day complication rate (76 vs. 85%,
p¼0.43), and similar 1- and 3-year survival in patients with
or without prior BS. On the other hand, data regarding
survival on the waiting list for LT after BS are controversial.
Idriss and coworkers documented a higher rate of dropout
and death on the waiting list among patients with prior BS
(33.3 vs. 10.1%; p¼0.002), and lower LT rate (48.9 vs. 65.2%;
p¼0.03). However, in the presented cohort the most com-
mon BS procedure was RYGB (63%).38
The feasibility of pre-LT SG was studied in well-compen-
sated LT candidates with median MELD score of 12, not
achieving an adequateweight reduction through amedically
supervised program. The authors did not observe deaths or
liver-related morbidity, and after 6 months, 28 out 32 (88%)
candidates were deemed eligible for LT.39
Recently, LT and simultaneous BS procedures such as SG
have been demonstrated feasible, with an acceptable rate of
perioperative complications,40 andgood long-term outcome,
showing a reduction of the post-LT rate of obesity and
metabolic complications. In a cohort of 29 patients (average
MELD at LT of 32.09.5 points) that underwent simulta-
neous LT and SG the authors reported two liver-related
deaths (recurrent hepatocellular carcinoma and cholestatic
allograft failure), one re-LT (early hepatic artery thrombosis),
and three re-operations due to bleeding, not related to the
SG. Gastric leak, severe gastroesophageal reflux, and persis-
tent renal failure are also reported, with more likely relation
to the SG component of the operation. However, when the
follow-updata are comparedwith the cohort of patientswith
medically complicated obesity, who achieved weight loss
target through lifestyle modification and underwent LT
alone, no difference in term of survival was found.41
The optimal timing to perform BS in LT candidates still
remains a controversial topic. An approach to BS in LT
candidates should be individualized. BS might be considered
prior to LT in situations where the weight loss may provide
an advantage of improving eligibility for LT. As discussed, this
approach may be feasible in compensated patients (Child A
or B7, MELD<15) listed with MELD-exceptions, without
signs of severe portal hypertension,42,43 but should not be
proposed to patients with more severe liver failure or portal
hypertension.
The published data on the simultaneous BSþ LT show this
technically feasible, but complications in the postoperative
phase are possible (stapleline leak, N/V, and GERD).41 De-
tailed discussions on the risk and benefit of the combined
procedure are advised. In addition, a multidisciplinary team
with specific experience in BS is crucial in achieving good
outcomes.
BS after LT aims to treat morbid obesity in efforts to reduce
the risk of metabolic complications after LT and improving
long-term outcomes. Reported series described an interval
fromLT toBS rangingbetween27and70months,44,45and thus
the safety and effectiveness of BS within the first 2 years of
transplant are unknown. Special care with respect to immu-
nosuppression should be taken on planning BS after LT, with
restrictive procedures having less effect on absorption than
malabsorptive procedures (which may require more careful
immunosuppression follow-up). Taken together, however,
published data suggest that BS does not significantly alter
immunosuppression levels and doses.45 As with any surgical
procedure, patients onmammalian target of rapamycin inhib-
itors (mTOR inhibitors) would need to be switched to other
immunosuppression regimens,46due to thehigh riskofwound
complications in patients on these drugs.
The overarching conclusion from this review shows, that
evidence suggesting a proportion of BS patients, especially
Seminars in Liver Disease Vol. 41 No. 4/2021 © 2021. The Author(s).
Bariatric Surgery in Cirrhosis Mendoza, Becchetti, et al.450
those receiving malabsorptive BS, may experience a rapid
deterioration of liver function such as to require LT. New
findings seem to highlight that severe malnutrition and
alcohol use disorder likely have a role in this progression.
Therefore, close follow-up of patientswith underlying chron-
ic liver disease after BS is required to early counteract or
reverse this progression and avoid, when possible, the need
for LT.
Pathophysiological Mechanisms Potentially
Driving Fibrosis Progression and Clinical
Decompensation after BS
As mentioned, malnutrition is associated with severe epi-
sodes of decompensation of liver disease after BS.20 The
histological lesions of lethal cases after initially used BS
procedures, as JIB, were severe steatohepatitis47,48
(►Fig. 1). As for the radiological findings, in the case series
of patients presenting with liver decompensation,20 among
17 patients, four showed significant hepatomegaly in com-
puterized tomography at time of decompensation (►Fig. 1,
panel E). All of these patients had no prior known liver
disease, underwent RYGB, and had a severe presentation of
decompensation, which required nutritional support.
The mechanism leading to decompensation of liver dis-
ease in the context of malnutrition or rapid weight loss after
BS remains poorly understood (►Fig. 2).
Rapid Weight Loss and Malnutrition
Malnutrition and malabsorption are the two main patho-
physiologic factors driving liver damage in patients under-
going BS. It has been postulated that protein and amino acid
malnutrition can rise or prolong lipid accumulation in the
liver, leading to exacerbation of preexisting steatosis.32 The
rapid and excessive weight loss after BS produces fast and
massive destruction of adipose tissue in visceral and pe-
ripheral deposits, leading to the release of free fatty acids
(FFAs) into plasma, reaching the liver through the portal
vein.49,50 This increases β-oxidation, de novo lipogenesis,
inflammation, and necrosis in the hepatocytes.50 Alterna-
tively, it has also been hypothesized that after BS with a
malabsorptive component, bacterial overgrowth of the
excluded small intestine and alterations in gut permeability
would lead to spill-over of endotoxins, reaching the liver
and triggering inflammation-related liver damage.32 How-
ever, experimental data supporting this hypothesis are
currently lacking.
Malabsorption of nutrients, vitamins, and tracemetals is a
common postoperative complication in BS patients. A recent
study showed that the presence of malnutrition as well as
sarcopenia may contribute to worse outcomes in patients
with a previous BS on the LT waiting list.38 Sarcopenia in
obese patients is thought to be partiallymediated by adipose
tissue-associated inflammation.51 The persistence of excess
adipose tissue after BS might perpetuate this mechanism,
which can be further aggravated by lack of mechanisms
promoting muscle anabolism (e.g., insufficient protein in-
take; excess of muscle catabolism during quick weight loss;
lack of exercising due to deconditioning). New insights have
highlighted that sarcopenia is significantly associated with
NASH and fibrosis, even in the early stage of the liver
disease.52 These findings have underlined the concept that
muscle quality matters over quantity and prompted the
hypothesis that sarcopenia may play an etiological role in
NASH. Insulin resistance (IR) and increased inflammation
play a key role in the development of both conditions.
Furthermore, myokines secreted by skeletal muscle (IL-6
and Irisin) are recognized to be involved in regulation of
somemetabolic variables, like the control of weight gain and
the IR.53
Fig. 1 Histological and radiological findings in patients with severe liver complications after RYGB. (A, B) Woman, 31 years of age, with
intraoperative liver biopsy without fibrosis, the figure shows the second biopsy obtained during the liver decompensation (3 year after surgery).
It showed cirrhosis associated with severe steatosis, steatohepatitis, and cirrhosis. (C, D) Woman, 45 years of age, biopsy 4 years after BS
showing high-grade steatosis and steatohepatitis with fibrous septa and remodeling typical of cirrhosis. (E) The CT showed large hepatomegaly,
severe steatosis, and signs of cirrhosis, and portal hypertension.
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Alcohol
Experimental and clinical evidence suggests that BS
increases the risk of developing an alcohol use disorder,54–56
with rates ranging from 8.5 to 21%,57,58 including cases of de
novo alcohol use disorder.20,59 As compared with other
surgical techniques, the prevalence of alcohol use disorder
is higher after RYGB.54,55,58,59 The hypothesized mechanism
includes “addiction transfer” in which patients replace one
addiction (food) for a new addiction (alcohol) after BS.60 It
has been hypothesized that neuro-hormonal shifts after BS
determine changes in reward processing and dopamine
signaling,61 and preliminary evidence from rats and imaging
studies in humans has suggested modifications in brain
dopamine functions following BS.62–64 In addition, hor-
mones as ghrelin and GLP-1 change after BS and play a
role in the gut-liver-brain axis modulating the dopamine
reward system. BS would then be followed by an increased
sensitivity to rewards alternatives to food, such as
alcohol.61,65
Alterations in pharmacokinetics following RYGB and
SG also likely play a role. BS accelerates alcohol absorp-
tion and warrants longer time to eliminate alcohol,
inducing a lower alcohol tolerance and leading to a faster
intoxication with less alcohol.66 It is well established that
the more rapid a substance reaches the brain, the higher
the risk of its addictiveness.67 Therefore, increased sen-
sitivity to alcohol after BS possibly influences a higher
risk of alcohol use disorder following BS.65 In a recent
population-based cohort of 8,966 patients followed up
for 7 years, the risk of alcohol dependence after RYGB was
almost double the risk compared with SG (incidence rate
ratio 1.8 [95% CI 1.1–2.8], for RYBG versus control,
p¼0.012, and 0.6 [95% CI 0.3–1.1] for SG versus control,
p¼0.073).6
Finally, critical social factors such as depression play a role
on increased alcohol consumption. The increased reward
sensitivity combined with unsolved presurgery factors (e.g.,
impulsiveness, binge-behavior traits) and post-surgery con-
ditions (e.g., depression, psychosocial factors)might enhance
the risk of new onset of alcohol use disorder.61 These prob-
lems typically tend to develop approximately 1 to 2 years
after BS.54,58
Fig. 2 Possible pathophysiological mechanisms of liver complications after BS. BS, bariatric surgery.
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Pre- and Postoperative Evaluation and
Management of Patients with Chronic Liver
Disease and Cirrhosis
Assessment of the Presence and Severity of Liver
Disease
The presence and severity of liver disease should be carefully
assessed prior to BS. Alcohol consumption and chronic viral
hepatitis should also be evaluated. NAFLD can be screened by
using continuous attenuation parameters (CAP score), ultra-
sound (or other imaging methods), and fibrosis assessments
by simple noninvasive tests such as NAFLD Fibrosis Score
(NFS) or fibrosis-4 index (FIB-4), alone or combined with
liver stiffness measurement (LSM) by transient elastogra-
phy-TE (using the XL probe),68which can help rule out severe
fibrosis and cirrhosis.10,69,70 Despite data in the specific
setting of patients candidate to BS are scarce, in the NASH
population, an LSM cut-off of less than 8 kPa could reliably
exclude advanced fibrosis and cirrhosis with a 94 to 100%
negative predictive value70,71; on the other hand, values
above 12 to 15 kPa have a high positive predictive value
(ranging from 80 to 90%) to detect advanced fibrosis or
cirrhosis. If advanced fibrosis or cirrhosis is diagnosed,
further diagnostic tests to address the presence of portal
hypertension are required to stratify the risk of surgical
complications and mortality. If BS is still an option, restric-
tive procedures, such as the sleeve gastrectomy, should be
preferred (►Fig. 3).
In cases where transient elastography does not provide
valid results, measurement of liver stiffness using two-
dimensional share wave elastography (2D-SWE) or magnetic
resonance elastography (MRE) can be considered. MRE has a
higher success rate and accuracy than ultrasound-based
technologies70 but is limited by cost and center specific
lack of available devices to assess morbidly obese patients.
In case noninvasive tests suggest cirrhosis (the choice of
the cut-off will depend on center-specific strategies maxi-
mizing the sensitivity or the specificity of the tests), liver
biopsy may be indicated to rule-in/rule-out this diagnosis.
The transjugular route might be preferable to minimize risk
in obese patients.72 In addition, this route allows the simul-
taneous measurement of the HVPG, allowing portal
Fig. 3 Suggested algorithm for the assessment of the presence and severity of liver disease preoperatively of BS (Adapted from Newsome et al9
and Castera et al70).
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hypertension assessment, which is a crucial factor while
assessing surgical risks. A recent study assessed the prog-
nostic role of HVPG in cirrhotic patients undergoing elective
extrahepatic surgery. The authors showed that HVPG>16
mm Hg is associated with higher 1-year mortality and an
HVPG>20mmHg identified a subset of patients at very high
riskof death (44%).27Whether this also applies specifically to
BS requires further study, but until those studies are per-
formed it is reasonable to follow this guidance.
The presence of splenomegaly associated with thrombo-
cytopenia, and the presence of gastroesophageal varices on
endoscopy can be considered surrogate signs of clinically
significant portal hypertension. Other proposed parameters
useful for preoperative risk stratification include the Child-
Pugh classification, MELD score, the ASA class, the Mayo
postoperative mortality risk, and the VOCAL-Penn model
(www.vocalpennscore.com).74 These tools provide addition-
al information to clinicians and the surgical team to guide the
decision of whether to perform the intervention.74However,
specific calibration of these models for BS is not available.
Presence of ascites indicates a decompensated stage of
cirrhosis, with very high risk of further decompensation and
mortality. In patients with decompensated cirrhosis and
morbid obesity, LT should be considered.74
Assessment of liver disease after BS requires routine liver
tests including bilirubin, transaminases, GGT, INR, and albu-
min. Patients with an intraoperative diagnosis of NASH and
significant/bridgingfibrosis or cirrhosis should be referred to
liver specialists for further evaluation. Patients with known
cirrhosis should undergo hepatocellular carcinoma screen-
ing and be closely monitored to prevent episodes of
decompensation.
Alcohol Assessment
The incidence of alcohol consumption increases over the post-
operative period of BS.20,54A recent prospective study based on
5,724 patients observed an increase in alcohol use disorder
incidence inpatientsundergoingSGandRYGBduring thefirst2-
year of follow-up.57 Female gender andRYGB are risk factors for
alcohol-related cirrhosis after BS.58 However, another study
described a similar risk for alcohol use disorder patients under-
going SG and RYGB.57 Preoperatively, patients should be edu-
cated about possible alcohol metabolism changes that may
makethemmoresusceptible toneworworseningalcohol abuse
after BS.75,76 Moreover, the guidelines recommend careful
preoperative screening for alcohol misuse.77
Based on the British Society of Gastroenterology and
British Association for the Study of Liver disease, the first
step would be to identify harmful drinking patterns (greater
than 50 units per week for men and 35 units per week for
women). For these high-risk groups, the next critical step is
to assess liver fibrosis and consider referral to the alcohol
service.69 For patients drinking less than this, initial screen-
ing with the brief version of Alcohol Use Disorders Identifi-
cation Test (AUDIT)-C score is recommended
(►Supplementary Table S1, available in the online version
only); a patient scoring  5 should proceed to the full 10-
item AUDIT questionnaire. A full AUDIT score  8 warrants
brief alcohol intervention and follow-up, but a full AUDIT
score>19 is considered a higher-risk group and referral to
the alcohol service is recommended.78,79
When alcohol use disorder is diagnosed prior to surgery,
abstinence should be recommended and monitored, and
patients should undergo a formal multidisciplinary evalua-
tion before performing BS.77 Postoperatively, clinicians and
mental health professionals following-up patients who un-
derwent BS should actively ask about alcohol consumption
and apply the AUDIT-C screening.80 Regular control with
routine liver tests such as GGT may increase the detection of
alcohol consumption. If there is doubt regarding alcohol
misuse and if an increase in liver tests might be attributable
to alcohol consumption, this could be screened either with
serumcarbohydrate-deficient transferrin,with phosphatidyl
ethanol, or with urinary ethyl glucuronide.81
Mental Health Assessment and Social Factors
Psychosocial factors affect long-term outcomes of BS. They can
affectadherencetothepostoperative recommendations,weight
loss outcomes, and comorbidity improvement.82 Therefore, a
pre-BS psychological assessment is required in the majority of
the BS programs. Domains for presurgical psychosocial evalua-
tion that need to be explored include weight history, eating
disorder symptoms (i.e., binge eating or night eat disorders),
social and family support, cognitive function, and structured
psychiatric diseases, mainly depression and anxiety.82 A study
conducted by the Longitudinal Assessment of Bariatric Surgery
ResearchConsortiumon199patientsfollowedupfor3yearshas
shownadecrease inpsychiatric disorders after BS.However, the
presence of post-BS eating disorders was associated with sub-
optimal weight loss.83 The same population followed-up for
7 years showed that mood and anxiety disorders impaired the
health-related quality of life, and decrease BS benefits, suggest-
ing that BS does not result in consistent long-term reductions in
mental disorders.83 Programs including psychological follow-
up after BS are often not available, therefore very little is known
about the best approach to improve mental health after BS.84
However, once a psychiatric disease has been properly framed,
these patients should be referred to a psychiatric and manage-
ment through both psychotherapy and medication should be
planned.
Nutritional Assessment
Sarcopenia, defined as a progressive and generalized loss of
skeletal muscle mass, strength, and function85 as well as
frailty86 have been recently identified as detrimental comor-
bidities in patients with cirrhosis. In the evaluation of the BS
candidate with liver disease, a preoperative assessment of
sarcopenia may be recommended. Indeed, the gold standard
for the quantification of skeletal muscle mass in liver disease
is nowadays considered skeletal muscle index (SMI). This is
obtained normalizing the cross-sectional area of the psoas
muscle (additionally para-spinal and abdominal wall
muscles) acquired with computed tomographic (CT) image
analysis at the third lumbar (L3) vertebra.87 Low SMI corre-
lates with poorer outcomes in several studies in patients
with liver disease.88 However, although CT scans are
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frequently performed in cirrhosis, this cannot be considered
a point-of-care test for sarcopenia. Therefore ,other reliable
and easily available tools, aiming to evaluate performance
status, and which indirectly estimate sarcopenia, have been
developed. Among them, the Liver Frailty Index is reliable
and reproducible89 and correlates with prognosis both in
cross-sectional studies and in the longitudinal assessment.90
To enhance postoperative recovery, protocols aimed at
improving physical fitness, such as the enhanced recovery
after surgery (ERAS) have been applied also in the BS setting.
They include physical pre-habilitation and rehabilitation
programs. A meta-analysis has shown that despite ERAS
protocol reduced the length of stay after BS, pre- and
rehabilitation had low or no influence on morbidity.91 There
is basically no data on the effect of physical activity on
counteracting sarcopenia in patients with liver disease and
concomitant BS. However, in a recent systematic review on
the impact of exercise on physical frailty in patients with
chronic liver disease and after-LT, the authors found that
exercise can improve physical frailty, particularly
functional/aerobic capacity and sarcopenia.92
Excessive weight loss and malnutrition play an essential
role in liver decompensation after BS. Moreover, obesity is
known to be paradoxically associated to some extent of
malnutrition, mainly deficiency of vitamin D and iron, which
are frequently reported before BS93 and can be enhanced
thereafter. Therefore, pre and mainly post-BS assessments of
malnutrition are paramount, to counteract multisystemic
complications, including liver dysfunction. Protein malnu-
trition plays a pivotal role in liver disease progression and
complications and should be as contrasted as possible in the
post-BS scenario. The European Practice Guidelines on nu-
trition in chronic liver disease suggests that the optimal daily
protein intake should not be lower than the recommended
1.2 to 1.5 g/kg.7 Oral multivitamins containing vitamins and
trace elements are administered systematically during the
weight loss phase (regardless of the intervention) and con-
tinuously after BS. Particular attention should be paid to
vitamin B12, folic acid, and thiamine to prevent neuropathy
and encephalopathy post-BS. Vitamins A, E, and K as well as
zinc, iron, and copper often require to be supplemented. In
addition, vitamin D and calcium deficiency if not properly
Table 1 Dietary recommendations and supplementation to avoid deficiency and malnutrition after BS adapted for patient with
liver disease7,77,94
Recommendations
Protein intake • Should constitute 10 to 35% of daily caloric intake.
• In patient with liver disease is required a protein intake between 1.2 and 1.5 g/kg while during the active weight loss
phase BPD may require 1.5 to 2.0 g/kg body weight per day.
Carbohydrates • Early postoperative—50 g/d.
• As diet intake increases—130 g/d.
Fat • 20–35% of the daily caloric intake; bulk of the fat intake should be unsaturated fat.
Vitamin D
and calcium
• Recommended preventative dose of vitamin D and calcium should be based on serum vitamin D levels, calcium and PTH.
• Recommended vitamin D3 dose is 3,000 IU daily.
• Calcium citrate preferentially in 2 doses, especially if with PPI.
Iron • Males and patients without a history of anemia: iron from multivitamin supplementation.
• Menstruating females and patients with RYGB, SG, or BPD: 45–60mg of elemental iron daily.
• Oral supplementation separately from calcium and PPI.
Folate • Regular folate daily dose from multivitamin supplementation.
• 800–1,000 μg oral folate daily in women of child-bearing age.
Thiamine • 50–100mg daily dose of thiamine from a B-complex supplement or high-potency multivitamin.
• When a thiamine deficiency is suspected it should be treated before or in the absence of laboratory confirmation and
monitored/evaluated for resolution of signs and symptoms due to potentially severe/unavertable condition. In this
setting parenteral administration should be preferred and magnesium sulfate added as co-factor.
• In patients with suspected AUD the treatment is started early.
Vitamin B12 • Regular B12 daily dose from multivitamin or B-complex supplementation.
• Supplementary dose should be evaluated according to B12 level and monthly parenteral administration should be
considered (1,000 μg).
Zinc and copper • 4 RDA of zinc and copper as part of routine multivitamin and mineral supplementation.
• Ratio of 8–15mg of supplemental zinc per 1mg of copper to minimize the risk of copper deficiency.
Vitamin
A, E and K
• Dosage as part of routine multivitamin and mineral supplementation.
• Higher maintenance doses of fat-soluble vitamins may be required for BS-patients with a previous history of deficiency,
pregnancy, or cholestasis present (evaluate parenteral administration).




Aim to avoid discomfort while the patients eat after BS
• Eat slowly and chew food extensively.
• Little meals, eventually increase the frequency.
• Eat no more than satiety.
• Avoid taking food and beverages at the same time.
Abbreviations: AUD, alcohol use disorder; BPD biliopancreatic diversion; BS, bariatric surgery; PPI, proton pump inhibitor; PTH, parathyroid
hormone; RDA, recommended dietary allowance; RYGB, Roux-en-Y-gastric-bypass; SG, sleeve gastrectomy.
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counteract can worsen bone loss, which is also affected by
the weight loss per se.94 Bone disease assessment requires
bone density scan, adequate therapy, and correct follow-
up. ►Table 1 describes the dietary recommendations and
supplementation to avoid deficiency and malnutrition
after BS.7,77,94
Patients who present with liver decompensation after
BS should receive a nutritional assessment by nutrition
specialists. They should receive oral supplementation tar-
geting 35 to 40 kcal/kg/day, including the recommended
protein intake of 1.2 to 1.5 g/kg/day7 by high-protein liquid
supplement, plus the substitution of vitamins and trace
elements. Patients not achieving sufficient oral caloric
intake may require enteral nutrition supplemented
through nasojejunal tube (NJT); if patients show intoler-
ance to NJT, they might require temporary parenteral
nutrition or undergo bariatric re-intervention. Laparosco-
pic reversal of BS has been described as improving malnu-
trition95 and consequently clinical stabilization of liver
disease.20
Fig. 4 Proposed actions to identify and follow-up liver disease and to potentially avoid severe decompensation in patients undergoing BS.
Abbreviations: BS, bariatric surgery; NAS, NAFLD Fibrosis Score; FIB-4, fibrosis-4 index; HVPG, hepatic venous pressure gradient; AUD, alcohol
use disorder; 2D-SWE, two dimensional share wave elastography; MRE, magnetic resonance elastography; AUDIT, alcohol use disorders
identification test; CDT, serum carbohydrate-deficient transferrin; uETG, with urinary ethyl glucuronide; CT, computed tomography.
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Alternatives to BS in Patients with Cirrhosis
In the last decade, bariatric endoscopy procedures have emerged
as a minimally invasive alternative to surgery.96 Endoscopic
therapies include duodenal and gastric devices, such as intra-
gastric balloons.97,98 Safety of these procedures is likely higher
than that of surgery, but data in patients with advanced chronic
liver disease/cirrhosis is lacking, and more research is needed to
clarify the real risk and benefits in these patients.99
Conclusion
BS can be an appropriate and effective treatment strategy for
patients with severely obese patients due to NAFLD or other
chronic liver diseases, including selected patients with com-
pensated cirrhosis. However, a subset of patientsmay showa
progression of liver disease to a cirrhosis stage, and can suffer
from short or long-term liver dysfunction and complications
of portal hypertension, requiring even LT after BS. New
findings seem to highlight that severe malnutrition related
to excessive weight loss after BS and de novo alcohol misuse
might have a role in the deterioration of liver function after
BS. There are possible pathophysiological mechanisms relat-
ed to these factors. Therefore, strict follow-up of weight loss
with adequate supplementation of vitamins and trace ele-
ments is the measure to avoid malnutrition and sarcopenia.
Prevention and early recognition of alcohol misuse pre-and
post-surgery is a major unmet need. Patients should be
educated about possible alcohol metabolism changes that
may make them more susceptible to new or worsening
alcohol misuse after BS. An overview of the approach to
apply before and after-BS to potentially avoid liver-related
complications is proposed in ►Fig. 4. A multidisciplinary
approach is the mainstay of these patients, and future
research is needed on risk factors and the impact of these
interventions to prevent liver-related complications.
Main Concepts and Learning Points
• Bariatric surgery (BS) can lead to improvement of liver
disease in patients with nonalcoholic steatohepatitis.
• BS can be considered in selected patients with compen-
sated cirrhosis without severe portal hypertension.
• A careful assessment of portal hypertension including
hepatic venous pressure gradient measurement and en-
doscopy is indicated in patients with signs of cirrhosis
before BS.
• Approximately 10% of BS patients with liver disease can
experience progression of liver disease and develop se-
vere decompensation or liver failure requiring liver
transplantation.
• Severe malnutrition linked to excessive weight loss, and
alcohol misuse are major risk factors for decompensation
of liver disease after BS.
• Alcohol abstinence and nutritional interventions can
allow for stabilization and recompensation of liver
disease.
• Multidisciplinary teams able to early detect malnutrition,
alcohol consumption, and psychiatric disorders after BS
are an unmet need in this field.
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